Korro Bio Strategy and Business Model

Executive Overview

Korro Bio is a clinical-stage biotechnology company focused on programmable RNA editing. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is trying to build a differentiated genetic-medicines platform by using short oligonucleotides to recruit endogenous adenosine deaminases acting on RNA (ADAR) and make specific edits at the RNA level rather than permanently changing DNA. Its core platform, OPERA, is aimed at diseases where a defined RNA edit could restore protein function or create a therapeutically useful change. Korro’s early strategic emphasis has been on liver-directed diseases, where oligonucleotide delivery is more established, with KRRO-110 for alpha-1 antitrypsin deficiency as its lead wholly owned program. In 2024, the company also announced a collaboration with Novo Nordisk in cardiometabolic disease, adding external validation and non-product revenue potential. The key issue for investors, partners, and future customers is not current commercial scale: Korro remains pre-commercial, and its FY2024 revenue was collaboration-related rather than driven by approved product sales. The real test is whether it can convert RNA-editing science into safe, reproducible, clinically meaningful human data.

Korro Bio at a Glance

Logo
Common name	Korro Bio
Full legal name	Korro Bio, Inc.
Headquarters	Cambridge, Massachusetts, United States
Ownership	Public company
Ticker	KRRO
Exchange	NASDAQ
Market Cap	$199.18M
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2018; became publicly listed through a 2023 merger with Frequency Therapeutics; announced a strategic collaboration with Novo Nordisk in 2024
Industry or industries	Biotechnology; genetic medicines; RNA editing
Key products or services	Investigational RNA-editing therapeutics, OPERA platform, discovery and development collaborations
Geographic footprint	U.S.-based operations with global clinical, manufacturing, and partnering reach
Business segments as officially reported	Single operating and reportable segment
Company website	https://www.korrobio.com/

1. What Is the Strategy of Korro Bio?

1a. What is the winning aspiration of Korro Bio?

Korro Bio’s winning aspiration is to prove that RNA editing can become a practical therapeutic modality and to build a multi-program genetic-medicines company around that capability. In plain terms, “winning” for Korro Bio means showing that its OPERA platform can generate precise, clinically meaningful edits in patients, starting with diseases where biology, delivery, and biomarkers are tractable. As of FY2024, the company’s public milestones were not mature-company targets such as revenue or margin goals. Instead, the scorecard was scientific and developmental: advance the lead program, generate human proof of mechanism, expand the pipeline, attract strong partners, and preserve enough capital to reach those inflection points.
1b. Where does Korro Bio play?

Korro Bio is not trying to compete across all of gene editing. It appears to be focusing on genetically defined diseases where a specific RNA edit could alter disease biology, especially in tissues that are already accessible to oligonucleotide delivery. Its initial emphasis has been liver-directed indications, including alpha-1 antitrypsin deficiency, because the liver is one of the more validated tissues for RNA-targeting medicines. Through its Novo Nordisk collaboration, Korro Bio is also extending into selected cardiometabolic targets. This is a relatively narrow “where to play” choice: editable RNA targets, clear molecular rationale, measurable biomarkers, and disease settings where a small company can create value before building a broad commercial franchise.
1c. How does Korro Bio plan to win?

Korro Bio’s “how to win” is differentiation through modality design. Rather than permanently editing DNA, it aims to make transient, programmable edits at the RNA level by recruiting endogenous ADAR enzymes. That approach could be attractive if it offers a useful balance of precision, manufacturability, dosing flexibility, and safety. The company is also trying to win by being selective: choosing disease targets where a defined edit is likely to matter clinically, where delivery is feasible, and where early biomarker readouts can support rapid learning. Commercially, it can create value in two ways: by keeping some programs wholly owned, especially in specialty or orphan settings, and by partnering broader opportunities where a larger company’s scale is useful.
1d. What capabilities must Korro Bio have in place?

To execute this strategy, Korro Bio needs strength in several tightly linked capabilities: RNA-editing guide design, oligonucleotide chemistry, tissue-specific delivery, off-target analysis, translational biology, biomarker development, and clinical development in rare disease. It also needs robust chemistry, manufacturing, and controls capabilities even if manufacturing is outsourced, because product consistency and regulatory readiness are central in genetic medicines. Beyond science, Korro Bio needs alliance-management skills for partnered programs, intellectual-property management around a young modality, and disciplined portfolio selection so it does not spread its resources too thinly.
1e. What management systems does Korro Bio require?

Korro Bio requires milestone-driven management systems more than scale-company operating systems. That means formal go/no-go portfolio governance, cash-runway planning, program reviews tied to preclinical and clinical data, regulatory and quality systems suitable for human trials, and clear alliance-governance mechanisms for external partnerships. In a company at this stage, management systems also need to reinforce prioritization: capital, talent, and external spending should move first to the programs most likely to generate decisive proof-of-concept data.

2. What Are the Current Strategic Initiatives of Korro Bio?

Advance KRRO-110 in alpha-1 antitrypsin deficiency. Korro Bio’s lead strategic initiative has been to move KRRO-110 through the preclinical-to-clinical transition and use it as the company’s first real test of platform validity. The program is designed to edit mutant SERPINA1 RNA in hepatocytes, with the goal of increasing functional alpha-1 antitrypsin while reducing the burden of toxic mutant protein. This matters strategically because positive human data would validate not just one asset but the broader RNA-editing approach.
Generate platform proof, not just asset progress. Korro Bio is not simply running a single-drug playbook. Its public messaging has emphasized building a reusable capability in guide design, editing efficiency, specificity, and translational measurement. The company needs each experiment and development step to improve the platform’s future hit rate across additional programs.
Execute the Novo Nordisk collaboration in cardiometabolic disease. The 2024 collaboration expanded Korro Bio beyond its lead wholly owned rare-disease program into selected cardiometabolic targets. Strategically, this adds external funding, third-party validation, and a second pathway to value creation. It also lets Korro Bio participate in larger disease areas without having to fund all downstream development itself.
Build translational and chemistry, manufacturing, and controls readiness. For a company like Korro Bio, platform science alone is not enough. It must develop manufacturing processes, analytical methods, bioanalytical assays, and biomarker plans that can stand up in regulatory interactions and early human studies. This is a critical strategic initiative because many genetic-medicines companies fail at the handoff from promising biology to reproducible clinical execution.
Preserve capital and keep the portfolio focused. As of FY2024, Korro Bio remained pre-commercial and financially dependent on cash reserves, collaboration proceeds, and capital markets. A practical strategic initiative, therefore, is disciplined portfolio management: fund the lead program and the highest-value platform work, use partnerships to extend reach, and avoid building a cost structure that outruns the company’s stage of development.

3. What Is the Business Model of Korro Bio?

Korro Bio’s business model is that of a pre-commercial platform biotech. Today, the company is creating economic value mainly by advancing proprietary drug candidates, building intellectual property around RNA editing, and entering collaborations that can bring in upfront payments, research funding, milestones, and potentially royalties. It is not yet a product-sales business.

What customers actually buy: Today, counterparties primarily buy access to Korro Bio’s platform, know-how, and program rights through partnerships. In the future, if one of its therapies is approved, healthcare systems would buy a precision medicine for narrowly defined patients.
Recurring or repeat-driven versus one-time: Collaboration upfronts are episodic. Research funding and milestones are partially recurring but inherently lumpy. Future product revenue could be more repeat-driven if RNA-editing therapies require redosing over time, although that depends on clinical durability and labeling.
Pricing power: If Korro Bio succeeds in rare or severe genetic disease, pricing power could come from clinical value, high unmet need, and limited direct alternatives. That said, pricing is not automatic; it would depend on demonstrated outcomes, safety, and payer acceptance.
Why the business mix matters: Wholly owned programs preserve more long-term economics but consume more cash. Partnered programs reduce financial burden and validate the platform, but they also cap the upside through shared economics.
What drives gross margin, operating margin, and cash generation: Gross margin is not yet the right lens because there is no scaled product revenue. Operating margin is negative by design because research and development spending dominates. Cash generation depends on partnership economics, equity financing, and spending discipline rather than internal cash flow.
Revenue model: Near term, the model is milestone-based and collaboration-driven. Long term, it could become a hybrid of specialty-biopharma product sales, license revenue, and royalties.

4. What Products and/or Services Does Korro Bio Sell?

As of FY2024, Korro Bio did not have an approved commercial product. Its most important offerings are investigational programs and platform capabilities.

KRRO-110: Korro Bio’s lead wholly owned program, aimed at alpha-1 antitrypsin deficiency. This is strategically the company’s most important near-term asset because it is the leading test of whether OPERA can work in humans.
OPERA platform: Korro Bio’s core RNA-editing platform, which uses engineered oligonucleotides to recruit endogenous ADAR for targeted RNA edits. In practice, this platform is both a discovery engine and a licensable asset.
Partnered discovery and development programs: The Novo Nordisk collaboration is an example of Korro Bio monetizing its science before commercialization. In these arrangements, the “product” is a mix of platform access, target-specific research, and option or license rights.
Pipeline expansion capabilities: Beyond named programs, Korro Bio is developing the chemistry, delivery, analytics, and translational toolkit needed to generate additional candidates. For a platform biotech, these capabilities are economically important even before they produce marketed products.

There is no large legacy commercial portfolio to analyze. The company’s value rests primarily on newer growth assets rather than mature products.

5. What Are the Key Competitors or Peers of Korro Bio?

Because Korro Bio is pre-commercial, its most relevant competitors are not companies fighting over current market share. They are a mix of direct RNA-editing peers, adjacent genetic-medicines platforms, and disease-level substitutes in target indications.

Wave Life Sciences: A close peer in oligonucleotide therapeutics and RNA editing, with particular relevance in liver-directed genetic disease and alpha-1 antitrypsin deficiency.
ProQR Therapeutics: Another company pursuing RNA editing as a therapeutic modality, making it a direct platform-level comparator.
Shape Therapeutics: A private genetic-medicines company with RNA-editing capabilities, relevant as a technology competitor even if less visible in public-market comparisons.
Beam Therapeutics: Focused on base editing at the DNA level. Not a direct RNA-editing company, but a substitute precision-editing competitor for some genetically defined diseases.
Prime Medicine: Another precise gene-editing peer using a different modality. Relevant where the clinical decision is not just which company wins, but which editing architecture becomes most attractive.
Intellia Therapeutics: A major in vivo gene-editing company with liver experience. It is a useful substitute competitor in genetic liver disease even though the underlying technology is different.
Alnylam Pharmaceuticals: Not an editing company, but an important benchmark in liver-targeted RNA therapeutics, rare-disease development, and specialty-market commercialization.
Arrowhead Pharmaceuticals: Another liver-focused RNA-therapeutics company whose delivery and development capabilities matter as a competitive reference point.
CSL Behring, Grifols, and Takeda: In alpha-1 antitrypsin deficiency, these companies are relevant at the disease level because augmentation therapy and related rare-disease expertise can shape the treatment landscape even if their modality is different.

6. What Is the Marketing Strategy of Korro Bio?

Korro Bio does not currently have a classic commercial marketing engine because it does not yet sell approved medicines. Its present-day marketing strategy is better understood as scientific, stakeholder, and partner communication.

The main channels appear to be investor presentations, conference presentations, publications, scientific messaging to key opinion leaders, and business-development outreach to potential collaborators. In that sense, Korro Bio’s closest equivalent to account-based marketing is targeted relationship building with a small number of sophisticated audiences: large pharma partners, specialist physicians, rare-disease investigators, and investors who understand platform biotechs.

If Korro Bio eventually commercializes a therapy in a rare liver or metabolic disease, its likely marketing model would be highly focused rather than broad-based: disease education, center-of-excellence engagement, patient-advocacy coordination, and payer-value communication. For now, marketing is a supporting capability, not the core differentiator. The core differentiator is the science and the data.

7. What Are the Key Customer Segments of Korro Bio?

Korro Bio does not yet have a diversified commercial customer base. Its customer segments are best understood in two layers: current economic counterparties and future healthcare customers if its therapies are approved.

Pharmaceutical partners: Today, the most tangible customer-like segment is large biopharma companies that may license or co-develop programs. The Novo Nordisk collaboration fits this category.
Specialist physicians and treatment centers: In rare genetic liver and metabolic disease, the eventual prescriber base would likely be concentrated among hepatologists, metabolic specialists, geneticists, and major referral centers.
Payers and health systems: These are critical economic decision makers for any future launch, especially if pricing reflects a high-value precision-medicine profile.
Patients and advocacy groups: They are not direct paying customers, but they are central stakeholders in trial recruitment, disease awareness, and eventual treatment adoption.

Korro Bio is therefore highly concentrated rather than broadly diversified. A small number of programs, partners, and specialist disease communities matter disproportionately to its future value.

8. What Is the Sales Model of Korro Bio?

As of FY2024, Korro Bio’s sales model was not a conventional pharmaceutical field-sales model because the company had no approved product. Instead, it had two practical go-to-market motions.

Partnership-led selling: Korro Bio can “sell” access to its platform and programs through business-development negotiations with pharmaceutical companies. This is a high-value, low-volume, senior-executive-led sales process rather than a scaled salesforce model.
Future specialty-biopharma selling: If a wholly owned rare-disease therapy reaches market, Korro Bio could potentially support it with a focused specialty commercial team in the United States, centered on a limited number of treatment centers and prescribing specialists.

Channel structure matters. A narrow specialist channel would improve customer intimacy and disease-level expertise, but it would only make economic sense for concentrated orphan markets. Broader indications, such as large cardiometabolic opportunities, are more likely to favor partnership-led commercialization. That channel choice directly affects pricing, scale requirements, and where consultants can help with launch planning, market access, and operating-model design.

9. In What Geographies Does Korro Bio Operate?

Korro Bio is headquartered in Cambridge, Massachusetts, and its operational footprint appears concentrated in the United States. That said, like many clinical-stage biotech companies, its real operating network extends beyond its headquarters through contract manufacturers, contract research organizations, clinical sites, and collaboration partners.

Its current and potential future reach is international in three ways. First, genetic-disease clinical development often uses sites across multiple countries because patient populations are small. Second, manufacturing and analytical work may be distributed across specialized external vendors. Third, collaboration economics can give Korro Bio exposure to markets well beyond the United States even before it builds its own international infrastructure.

Korro Bio does not appear to operate a large owned plant, warehouse, or global distribution network. Operationally, it is concentrated; strategically, its addressable footprint is global.

10. Who Are the Owners of Korro Bio?

Korro Bio is a publicly traded company listed on Nasdaq under the ticker KRRO. As a public biotech, its ownership structure is time-sensitive and typically includes a mix of institutional investors, legacy venture holders, public-market biotech specialists, and company insiders.

The key structural point is that Korro Bio emerged as a public company through its 2023 merger with Frequency Therapeutics, and legacy Korro equity holders became the majority owners of the combined company at that time. Korro Bio does not appear to be defined by a single controlling shareholder in the way a founder-controlled technology company or family-controlled industrial firm might be.

11. How Is Korro Bio Organized?

Korro Bio is organized more like a focused development-stage biotech than a diversified pharmaceutical company. It appears to operate as a single reportable segment, which is typical for pre-commercial life-sciences companies that are managed around a common platform and portfolio rather than separate revenue-generating divisions.

At a practical level, the organization is likely built around functional groups such as discovery research, translational biology, clinical development, regulatory affairs, chemistry, manufacturing, and controls, business development and alliance management, and general and administrative support. Program teams sit across those functions, with the lead asset and partnered programs receiving cross-functional attention.

This structure matters because Korro Bio’s main challenge is prioritization, not empire management. A small number of scientific and development decisions can have an outsized effect on valuation, capital needs, and partnering options.

12. How Does Korro Bio Operate?

Korro Bio’s day-to-day operation revolves around converting RNA-editing hypotheses into development candidates and then into clinical data. Unlike a mature commercial biopharma company, it does not primarily create value through large-scale manufacturing or sales execution. It creates value through design, experimentation, outsourcing control, and portfolio decisions.

Target and edit selection: The company identifies diseases where a specific RNA edit could plausibly change the course of disease.
Guide and chemistry design: Scientists design oligonucleotides that can recruit endogenous ADAR and drive the intended edit with acceptable specificity.
Preclinical validation: Programs are tested in cellular and animal systems to measure editing efficiency, protein restoration, biomarker movement, and safety signals.
External manufacturing and analytical control: Korro Bio works with specialized third parties to manufacture materials and run analytical assays, while retaining responsibility for process definition, quality oversight, and regulatory compliance.
Clinical execution: Once a program is ready, the company relies on clinical sites, contract research organizations, and internal development teams to dose patients, monitor safety, and collect biomarker data.
Capital and alliance management: Management must continuously decide which programs to fund internally, which to partner, and how to pace spending against expected catalysts.

The main operating bottlenecks are not unusual for a company in this field: tissue delivery, edit efficiency, off-target control, chemistry and manufacturing consistency, and patient recruitment in rare disease.

13. What Are the Growth Opportunities for Korro Bio?

Clinical proof-of-concept in KRRO-110: The single biggest growth opportunity is turning the lead program into convincing human data. If that happens, the value of the platform could re-rate sharply.
Expansion into additional liver indications: Liver delivery is one of the more established routes for oligonucleotide medicines. Success there could support a broader franchise of genetically defined hepatic and metabolic diseases.
Collaboration-led growth in larger markets: The Novo Nordisk collaboration shows a path into cardiometabolic disease without requiring Korro Bio to build all capabilities alone. More deals of that type could broaden the revenue base and reduce financing pressure.
Platform monetization: Even before full commercialization, Korro Bio can create value through options, licenses, milestones, and royalties tied to its RNA-editing capability.
Future specialty commercialization: If a wholly owned rare-disease therapy reaches approval, Korro Bio could potentially capture higher economics through a focused launch rather than out-licensing everything.

The main constraints are equally clear: clinical risk, regulatory risk, the challenge of proving safety and specificity, strong competition from other RNA and gene-editing modalities, and the capital intensity of staying in the clinic long enough to prove the model.

14. What Is the History of Korro Bio?

Korro Bio was founded in 2018 to develop therapeutic RNA editing. From the beginning, its core idea was that endogenous RNA-editing enzymes could be recruited with designed oligonucleotides to make precise edits without permanently changing DNA.

The company’s biggest corporate turning point came in 2023, when it merged with Frequency Therapeutics, a Nasdaq-listed biotech. That transaction gave Korro Bio a public-company platform, access to public-market capital, and a cleaner route to funding its pipeline than remaining private indefinitely. After the merger, the combined company operated under the Korro Bio name and strategy rather than Frequency’s legacy regenerative-medicine focus.

In 2024, Korro Bio added another important milestone by announcing a collaboration with Novo Nordisk in cardiometabolic disease. That agreement mattered not only for funding but also because it signaled outside confidence in the company’s platform at an early stage.

15. What Are the Key Suppliers to Korro Bio?

Suppliers matter to Korro Bio even though they are not the story in the way they would be for a manufacturer. As a clinical-stage biotech, the company depends heavily on specialized external partners rather than commodity vendors.

Oligonucleotide manufacturing partners: Contract development and manufacturing organizations that can produce research-grade and good manufacturing practice material are among the most important suppliers.
Raw-material and chemistry suppliers: Nucleotide building blocks, conjugation components, reagents, and formulation materials are critical inputs.
Contract research organizations: These vendors support toxicology, bioanalysis, clinical-trial execution, data management, and monitoring.
Specialized laboratories and assay providers: Editing analytics, biomarker testing, and quality-control work often rely on outside specialists.
Software, instrumentation, and research-tool providers: While less strategic than manufacturing partners, these suppliers still support discovery productivity and data quality.

Supplier structure matters because a small number of high-specification vendors can become timeline-critical. In biotech, a manufacturing delay or assay problem can move a clinical program by months, which in turn affects valuation and financing needs.

16. What Is the Technology Strategy of Korro Bio?

Korro Bio’s technology strategy is central to the company’s identity. It is not using technology merely as an internal efficiency tool; the technology itself is the product engine. The company’s OPERA platform is designed to recruit endogenous ADAR to specific RNA transcripts using oligonucleotides, aiming for precise edits that can change protein output without making permanent genomic changes.

The strategy appears to rest on several layers of technology working together: sequence and guide design, oligonucleotide chemistry, tissue delivery, off-target detection, bioanalytical measurement, and translational modeling. In a company like Korro Bio, competitive advantage does not come from any one of these in isolation. It comes from making them work as a system.

Korro Bio’s technology strategy also seems intentionally pragmatic. The company has focused first on tissues and disease settings where delivery is more realistic, rather than trying to prove RNA editing everywhere at once. That kind of technological narrowing is often a sign of discipline rather than limited ambition.

17. What Is the R&D Strategy of Korro Bio?

Korro Bio’s research and development strategy appears designed to maximize learning per dollar and per program. The company is focusing on indications where four things align: a clear disease-causing RNA target, a plausible therapeutic edit, measurable biomarkers, and delivery feasibility. That is why liver-directed disease has been such an important early focus.

KRRO-110 serves as the lead R&D test case, but the broader aim is platform validation. The company’s R&D spend is therefore doing two jobs at once: advancing a single candidate and improving the underlying editing engine for future programs. That makes translational assays, specificity work, chemistry optimization, and delivery science especially important.

The Novo Nordisk collaboration also fits the R&D strategy. It allows Korro Bio to push its platform into additional biology with shared economics and outside resources. For a company at this stage, that is often a more efficient way to broaden the pipeline than self-funding every indication internally.

18. What Is the Finance Strategy of Korro Bio?

Korro Bio’s finance strategy is best understood as runway management in support of scientific inflection points. As a pre-commercial biotech, it is not optimizing for current earnings. It is optimizing for enough cash, enough flexibility, and enough non-dilutive support to reach value-creating data readouts.

That has several practical implications. First, research and development gets the majority of economic attention, while selling infrastructure remains limited. Second, collaboration capital matters because it can fund work without the same dilution as repeated equity raises. Third, portfolio discipline is itself a finance strategy: every additional program competes for scarce cash.

The merger that made Korro Bio public and the later Novo Nordisk collaboration are both consistent with this approach. They show a company using corporate finance and partnering as strategic tools. Investors should therefore think less about traditional profitability metrics and more about cash burn, milestone timing, and whether the company is spending in a way that increases the probability of platform validation.

19. What Major Acquisitions Has Korro Bio Made?

Korro Bio has not been a serial acquirer. Its most important strategic transaction has been a merger rather than a conventional acquisition.

2023 merger with Frequency Therapeutics: This was the transformative corporate transaction in Korro Bio’s history. Functionally, it provided public-company status, access to capital, and a platform for funding the RNA-editing strategy.
Partnerships rather than acquisitions: As of FY2024, Korro Bio appeared to rely more on collaborations and licensing structures than on buying companies or commercial assets. The Novo Nordisk deal is strategically important, but it is a collaboration, not an acquisition.

That pattern makes sense for a company at Korro Bio’s stage. Acquisitions would add complexity and cash needs, while partnerships let it extend the platform with less balance-sheet strain.

20. How Companies Like Korro Bio Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants across more than 50 countries, including alumni of McKinsey, Bain, BCG, and other top firms. A company like Korro Bio can use Umbrex when it needs top-tier problem solving in a focused area but does not need the cost or scale of a full consulting team. For a clinical-stage genetic-medicines company, the most useful projects are usually tightly scoped, analytically demanding, and closely linked to a few major strategic decisions.

RNA-editing portfolio prioritization: Build a decision framework to rank new targets by editability, disease attractiveness, delivery feasibility, competitive intensity, and capital requirements.
AATD market and treatment-journey analysis: Map the future commercial landscape for KRRO-110, including current standard of care, specialist referral patterns, patient segmentation, and likely adoption barriers.
Target product profile and clinical-development strategy: Pressure-test endpoint strategy, biomarker hierarchy, patient-selection logic, and evidence needs for early-stage rare-disease trials.
Partnering strategy for non-core programs: Identify which opportunities should remain wholly owned versus partnered, and develop a deal-screening framework for future collaborations.
Alliance-governance support: Design meeting cadences, escalation paths, decision rights, and KPI dashboards for collaborations such as large-pharma partnerships.
Chemistry, manufacturing, and controls operating model: Assess outsourcing structure, CDMO network design, risk concentration, and stage-appropriate build-versus-buy choices.
Rare-disease launch blueprint: Create a specialty-commercial model for a potential orphan launch, including field-force sizing, account targeting, patient-services design, and market-access priorities.
Finance and runway scenario planning: Model alternative capital-allocation paths based on clinical timing, partnership assumptions, and portfolio breadth.
Organization design for scale-up: Help management define how to evolve from a platform research company into a multi-program development organization without overbuilding overhead.
Competitive-intelligence and modality strategy: Track RNA-editing, RNA-therapy, and gene-editing peers to clarify where Korro Bio should differentiate and where it should avoid direct competition.